[Skip to Navigation]
Views 4,090
Citations 0
Brief Report
March 11, 2021

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer

Author Affiliations
  • 1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York
  • 3Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • 5Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. Published online March 11, 2021. doi:10.1001/jamaoncol.2021.0057
Key Points

Question  Does irradiation dose escalation to doses known to cure other cancers improve local tumor control and survival for patients with localized pancreatic cancer?

Findings  Ablative radiation therapy after induction chemotherapy in 119 patients with locally advanced unresectable pancreatic cancer was associated with a 2-year local tumor progression rate of only 32.8% and a 2-year overall survival rate of 38% from the time of irradiation.

Meaning  Hypofractionated ablative radiation therapy was associated with durable control of the primary tumor leading to favorable survival outcomes.


Importance  Surgical resection has been considered the only curative option for patients with pancreatic cancer. Nonoperative local treatment options that can provide a similar benefit are needed. Emerging radiation techniques that address organ motion have enabled curative radiation doses to be given in patients with inoperable disease.

Objective  To determine the association of hypofractionated ablative radiation therapy (A-RT) with survival for patients with locally advanced pancreatic cancer (LAPC) treated with a novel radiation planning and delivery technique.

Design, Setting, and Participants  This cohort study included 119 consecutive patients treated with A-RT between June 2016 and February 2019 and enrolled in a prospectively maintained database. Patients were treated with a standardized technique within a large academic cancer center regional network. All patients with localized, unresectable, or medically inoperable pancreatic cancer with tumors of any size and less than 5 cm luminal abutment with the primary tumor were eligible.

Interventions  Ablative RT (98 Gy biologically effective dose) was delivered using standard equipment. Respiratory gating, soft tissue image guidance, and selective adaptive planning were used to address organ motion and limit the dose to surrounding luminal organs.

Main Outcomes and Measures  The primary outcome was overall survival (OS). Secondary outcomes included incidence of local progression and progression-free survival.

Results  Between 2016 and 2019, 119 patients (59 men, median age 67 years) received A-RT, including 99 with T3/T4 and 53 with node-positive disease, with a median carbohydrate antigen 19-9 (CA19-9) level greater than 167 U/mL. Most (116 [97.5%]) received induction chemotherapy for a median of 4 months (0.5-18.4). Median OS from diagnosis and A-RT were 26.8 and 18.4 months, respectively. Respective 12- and 24-month OS from A-RT were 74% (95% CI, 66%-83%) and 38% (95% CI, 27%-52%). Twelve- and 24-month cumulative incidence of locoregional failure were 17.6% (95% CI, 10.4%-24.9%) and 32.8% (95% CI, 21.6%-44.1%), respectively. Postinduction CA19-9 decline was associated with improved locoregional control and survival. Grade 3 upper gastrointestinal bleeding occurred in 10 patients (8%) with no grade 4 to 5 events.

Conclusions and Relevance  This cohort study of patients with inoperable LAPC found that A-RT following multiagent induction therapy for LAPC was associated with durable locoregional tumor control and favorable survival. Prospective randomized trials in patients with LAPC are warranted.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Ablative radiation therapy for inoperable pancreatic cancer: promising but more evidence is necessary
    Fu-yu Li, MD, PhD | West China Hospital, Sichuan University
    With great interest, we have read this single-center, retrospective non-randomized study from Reyngold and colleagues entitled “Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer”.[1] Within their study, ablative radiation therapy (ART) in patients with locally advanced pancreatic cancer (LAPC) was associated with durable locoregional tumor control, improved overall survival (OS), and lower adverse events. The performed study is interesting and so are the results. However, we would like to mention some remarks.

    First, 55.5% of patients in this study received modified FOLFIRINOX induction chemotherapy and have shown better results than the study with conventional
    chemoradiotherapy. In contrast, the patients in the previous studies received conventional radiotherapy after Gemcitabine-based induction chemotherapy.[2, 3] Studies have shown the superiority of FOLFIRINOX based chemotherapy regimen over Gemcitabine.[4] Induction chemotherapy with a modified FOLFIRINOX regimen must have contributed to the favorable outcomes in this study.

    Second, on comparing the survival outcomes of the current study with a patient-level meta-analysis of FOLFIRINOX chemotherapy, we have identified that median OS, 2-year OS, and progression-free survival were similar to the current study.[5] So we are concerned about the added benefit of ART. Moreover, the author included 83% of patients with radiographic T3/T4 disease, it would be of interest to report the number of patients with major vessel invasion, which is associated with poor outcomes in patients with pancreatic cancer. An in-depth analysis of this group of patients and their survival outcomes after chemoradiotherapy will lead to a better understanding of this therapy.

    It is worth mentioning that the author has identified the postinduction reduction of carbohydrate antigen (CA) 19-9 was associated with improved survival outcomes in both univariate and multivariate analysis. This group of patients may have better outcomes during further investigations. Finally, further multicenter trials with a direct comparison of mFOLFIRINOX induction chemotherapy followed by ART and mFOLFIRINOX chemotherapy without ART are needed to understand the efficacy and safety of this rising alternative therapy for patients with LAPC.

    Authors: Parbatraj Regmi, MD; Fei Liu, MD; Fu-Yu Li, MD, PhD


    1. Reyngold M, O'Reilly EM, Varghese AM et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 2021.
    2. Hammel P, Huguet F, van Laethem JL et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315: 1844-1853.
    3. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599.
    4. Conroy T, Hammel P, Hebbar M et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018; 379: 2395-2406.
    5. Suker M, Beumer BR, Sadot E et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17: 801-810.